market folly

Richard Gerson's hedge fund firm Falcon Edge Capital has filed a 13G with the SEC regarding shares of Tekmira Pharma (TKMR).  Per the filing, Falcon Edge now owns 9.9% of the company with over 2.22 million shares.

This is a newly disclosed equity position for the hedge fund and the filing was due to activity on January 12th.  Tekmira recently bought OnCore Biopharma, creating a company focused on creating Hepatitis B treatments.

Prior to founding Falcon Edge, Gerson worked with John Griffin at Blue Ridge Capital, a fund the site has tracked for many years.

Per Google Finance, Tekmira Pharma is "a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Its product candidates include TKM-HBV, TKM-PLK1, TKM-Ebola and TKM-Marburg. TKM-HBV is an RNAi therapeutic for the treatment of Hepatitis B infection. The Company’s lead oncology product candidate, TKM -PLK1 is an oncology product platform that targets polo-like kinase 1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target. TKM-ALDH2 is an application of RNAi for alcohol use disorder with a target patient population who have moderate to severe alcohol use disorder. TKM-Ebola is an anti-Ebola viral therapeutic being developed under a contract with the United States Department of Defense Joint Project Manager Medical Countermeasure Systems. TKM-Marburg is used to treat hemorrhagic fever viral infections.."